再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

盘前交易 11-09 06:49:06 EST

904.35

+1.45

+0.16%

盘前911.00

+6.65+0.74%

06:38 EST

最高911.64	最低887.04	成交量112.29万
今开887.22	昨收902.90	日振幅2.72%
总市值931.07亿	流通市值894.25亿	总股本1.03亿
成交额10.16亿	换手率1.14%	流通股本9,888万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":904.35,"timestamp":1793998800000,"preClose":902.9,"halted":0,"volume":1122871,"hourTrading":{"tag":"盘前","latestPrice":911,"preClose":904.35,"latestTime":"06:38 EST","volume":221,"amount":201647.08304,"timestamp":1794224284802,"change":6.65,"changeRate":0.007353,"amplitude":0.046148},"delay":0,"changeRate":0.0016059364270683857,"floatShares":98883600,"shares":102954988,"eps":45.166714,"marketStatus":"盘前交易","change":1.45,"latestTime":"11-09 06:49:06 EST","open":887.22,"high":911.64,"low":887.04,"amount":1015802106.1112,"amplitude":0.027246,"askPrice":934,"askSize":1,"bidPrice":911,"bidSize":5,"shortable":3,"etf":0,"ttmEps":45.166714,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794234600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":904.35,"dividendRate":0.004091,"preHourTrading":{"tag":"盘前","latestPrice":911,"preClose":904.35,"latestTime":"06:38 EST","volume":221,"amount":201647.08304,"timestamp":1794224284802,"change":6.65,"changeRate":0.007353,"amplitude":0.046148},"postHourTrading":{"tag":"盘后","latestPrice":900,"preClose":904.35,"latestTime":"19:58 EST","volume":200462,"amount":181284259.4365,"timestamp":1794013128144,"change":-4.35,"changeRate":-0.00481,"amplitude":0.00481},"volumeRatio":0.6578166666908258,"impliedVol":0.4579,"impliedVolPercentile":0.96},"requestUrl":"/m/hq/s/REGN/wiki","defaultTab":"wiki","newsList":[{"id":"1186649481","title":"异动解读｜再生元制药公司盘中下跌3.02%，财报利好兑现后股价延续回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1186649481","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186649481?lang=zh_cn&edition=full","pubTime":"2026-11-06 04:55","pubTimestamp":1793912105,"startTime":"0","endTime":"0","summary":"11月6日，再生元制药公司盘中下跌3.02%，报902.54美元／股，成交额9.81亿美元。从公开消息看，此次异动仍主要围绕三季度业绩大幅超预期后的资金回吐。公司此前披露，三季度营收51.16亿美元，同比增长36.3%；非GAAP摊薄每股收益20.07美元，明显高于市场预期的16.19美元，并将全年净产品毛利率指引上调至约80%。但在前期财报驱动股价大涨后，短线市场表现为利好兑现下的回吐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再生元财报超预期，股价高位回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164168589","title":"异动解读｜再生元制药公司盘中下跌3.1%，机构上调目标价后市场回吐涨幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1164168589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164168589?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:44","pubTimestamp":1793807072,"startTime":"0","endTime":"0","summary":"11月4日，再生元制药公司盘中下跌3.1%，报951.4059美元／股，成交额3.41亿美元。此次异动可对应的公开消息面，仍主要围绕机构上调目标价及公司此前披露的三季度超预期业绩，但股价在前期利好兑现后出现回吐。最新调整显示，Bernstein将目标价由756美元上调至812美元，市场平均评级为overweight，平均目标价为973.04美元。业绩方面，公司三季度营收51.16亿美元，同比增长36.3%；非GAAP摊薄每股收益20.07美元，明显高于预期的16.19美元，并将全年净产品毛利率指引上调至约80%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"机构上调目标价，再生元盘中下跌回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190342582","title":"异动解读｜再生元制药公司盘前上涨3.05%，机构上调目标价叠加三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190342582","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190342582?lang=zh_cn&edition=full","pubTime":"2026-11-04 21:08","pubTimestamp":1793797718,"startTime":"0","endTime":"0","summary":"11月4日，再生元制药公司盘前上涨3.05%，报1003.0018美元／股，成交额168.73万美元。此次异动的消息面催化，主要来自机构继续上调目标价，最新调整显示目标价由756美元上调至812美元；目前市场平均评级为overweight，平均目标价为973.04美元。同时，公司此前披露的三季度业绩显著超预期，进一步强化市场情绪。当季营收51.16亿美元，同比增长36.3%；非GAAP摊薄每股收益20.07美元，明显高于市场预期的16.19美元，并将全年净产品毛利率指引上调至约80%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再生元盘前上涨，业绩超预期叠加目标价上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110743187","title":"异动解读｜再生元制药公司盘中上涨3.24%，获机构上调目标价且三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1110743187","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110743187?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:50","pubTimestamp":1793631024,"startTime":"0","endTime":"0","summary":"11月2日，再生元制药公司盘中上涨3.24%，报958.325美元/股，成交额2.54亿美元。此次异动的直接催化，来自机构继续上调目标价。最新消息显示，Bernstein将其目标价由756美元上调至812美元；目前市场对该股平均评级为overweight，平均目标价为973.04美元。同时，公司此前披露的三季度业绩明显超预期，也持续强化市场情绪。公司当季营收51.16亿美元，同比增长36.3%；非GAAP摊薄每股收益20.07美元，高于预期的16.19美元，并上调全年净产品毛利率指引至约80%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再生元获机构上调目标价，三季度业绩超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680754916","title":"蒙特利尔银行：将艾伯维(ABBV.US)目标价从300美元上调至340美元。再生元制药公司(REGN.US)的目标价从9","url":"https://stock-news.laohu8.com/highlight/detail?id=2680754916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680754916?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:14","pubTimestamp":1793621659,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IYH","LU0882574055.USD","IBBQ","LU2112291526.USD","FHLC","GLAM","IE0002270589.USD","LU0310800379.SGD","LU0256863811.USD","LU2237443895.HKD","LU2237443978.SGD","TBXU","LU0211327993.USD","LU1496350502.SGD","IBB","LU1923622614.USD","AGNG","IE00BBT3K403.USD","PPH","IE00B19Z3581.USD","REGN","FTXH","LU0029864427.USD","LU0823434740.USD","LU0861579265.USD","LU0069063385.USD","ABBV","JDOC","IE00B3PB1722.GBP","MEDX","XLV","IXJ","LU0965509010.AUD","LU0057025933.USD","IE000BZT7R73.USD","LU2106854487.HKD","LU2468319806.SGD","LU1057294990.SGD","TRUH","UUP","LU1670627923.USD","LU1934455277.USD","UDN","BK4550","LU1037948541.HKD","IE00B4R5TH58.HKD","VHT","RXL","PJP","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166668424","title":"一周美股牛榜 | 滨特尔、Vertiv因业绩超预期上周飙升近20%；Carvana上涨逾18%，GEN劲升17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166668424","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166668424?lang=zh_cn&edition=full","pubTime":"2026-11-02 10:49","pubTimestamp":1793587775,"startTime":"0","endTime":"0","summary":"公司预计第三季度营收为13.7亿至13.9亿美元，同比增长10%至12%。预计当季调整后每股收益为0.73至0.75美元，同比增长15%至18%。","market":"us","thumbnail":"https://static.tigerbbs.com/1d6a4572b675796b315e560ea7fe3401","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1d6a4572b675796b315e560ea7fe3401"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTL","HII","CMGG","NCLH","VRT","PNR","CMG","REGN","GM","CVNA","CVNY","GEN","HILS.UK","VRC","GPN","CMG.AU","CVNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679721702","title":"再生元制药公司(REGN.US)涨13.6%，第三季度业绩超预期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2679721702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679721702?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:46","pubTimestamp":1793367981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU2106854487.HKD","LU0109394709.USD","LU2362541273.HKD","LU2237438978.USD","BBH","IBB","LU0882574055.USD","LU0289739699.SGD","TBXU","LU2324357040.USD","LU0053666078.USD","LU2089984988.USD","LU0058720904.USD","LU2362541513.USD","LU2362540622.SGD","LU0114720955.EUR","LU0823434583.USD","REGN","IBBQ","LU1974910355.USD","LU1917777945.USD","LU2023250504.SGD","BK4139","BK4585","LU2468319806.SGD","BK4588","LU0823416689.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173229374","title":"异动解读｜再生元制药公司盘中上涨4.13%，三季度业绩大幅超预期并上调利润率指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1173229374","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173229374?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:34","pubTimestamp":1793367264,"startTime":"0","endTime":"0","summary":"10月30日，再生元制药公司盘中上涨4.13%，报910.0美元/股，成交额2.61亿美元。此次异动的核心催化，是公司最新披露的三季度业绩显著超预期，并上调全年净产品毛利率指引至约80%，同时下调销售及管理费用与资本开支指引。公司当季营收51.16亿美元，同比增长36.3%，高于市场预期的45.42亿美元；非GAAP摊薄每股收益20.07美元，同比增长69.7%，明显高于预期的16.19美元。财报前后，多家机构继续上调目标价，进一步强化了市场对其后续产品增长与盈利弹性的乐观预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再生元业绩大超预期，盘中强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679429021","title":"再生元制药(REGN.US)Q3业绩超预期 上调全年净产品毛利率指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2679429021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679429021?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:58","pubTimestamp":1793357928,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再生元制药发布 2026 年第三季度业绩：总营收 51.158 亿美元，同比增长 36.3%，高于 IBES 一致预期的 45.42 亿美元;GAAP 摊薄每股收益 18.45 美元、同比增 35.5%。非 GAAP 摊薄每股收益 20.07 美元、同比增 69.7%，较 IBES 预期的 16.20 美元高出约 24%。公司上调 2026 年净产品毛利率指引至约 80%，同时下调销售及管理费用与资本开支指引。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["REGN","LU2468319806.SGD","01477","BK4588","LU2362541513.USD","LU0109394709.USD","BK1574","LU2089984988.USD","BK4139","BBH","LU2023250504.SGD","LU0289739699.SGD","LU0053666078.USD","LU0823434740.USD","LU0889565916.HKD","LU0114720955.EUR","LU0823416689.USD","BK4585","LU0320765992.SGD","LU1917777945.USD","BK1191","LU2324357040.USD","IBBQ","LU0823434583.USD","LU2362541273.HKD","LU2237438978.USD","LU2362540622.SGD","LU0058720904.USD","TBXU","LU2106854487.HKD","LU0882574055.USD","LU1974910355.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679290290","title":"再生元制药(REGN.US)Q3业绩超预期 上调全年净产品毛利率指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2679290290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679290290?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:58","pubTimestamp":1793357928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2324357040.USD","BK4588","LU0889565916.HKD","LU0823434583.USD","LU0109394709.USD","IBBQ","LU0823416689.USD","LU0289739699.SGD","LU0320765992.SGD","LU2468319806.SGD","LU1974910355.USD","LU0114720955.EUR","TBXU","BBH","LU2362540622.SGD","BK4585","LU2023250504.SGD","LU2362541513.USD","LU1917777945.USD","LU0053666078.USD","LU2089984988.USD","IBB","LU0058720904.USD","REGN","BK4139","LU2362541273.HKD","LU2237438978.USD","LU0823434740.USD","LU0882574055.USD","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138441085","title":"异动解读｜再生元制药公司盘前上涨3.81%，三季度业绩大幅超预期后获机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1138441085","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138441085?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:40","pubTimestamp":1793356846,"startTime":"0","endTime":"0","summary":"10月30日，再生元制药公司盘前上涨3.81%，报850.0美元/股，成交额64.3万美元。此次异动的核心催化来自公司最新披露的三季度业绩显著超预期，叠加财报前后机构继续上调目标价。公司当季调整后每股收益20.07美元，明显高于市场预期的16.19美元；销售额51.16亿美元，高于预期的45.42亿美元。在此之前，Canaccord Genuity已将其目标价由875美元上调至922美元，Evercore ISI也将目标价由850美元上调至900美元，显示卖方对公司基本面与后续产品增长预期偏积极。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再生元业绩超预期，盘前走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117884401","title":"财报前瞻 | 再生元制药公司本季度营收预计增长20.91%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1117884401","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117884401?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:20","pubTimestamp":1792714846,"startTime":"0","endTime":"0","summary":"再生元制药公司将于2026年10月30日发布最新季度财报，市场关注重点为合作与产品收入双轮驱动下的利润弹性及眼科与免疫业务的增长可持续性。上季度再生元制药公司营收为42.91亿美元，同比增长16.74%；毛利率为48.54%；归属于母公司的净利润为12.97亿美元，净利率为30.23%；调整后每股收益为14.29美元，同比增长10.86%。根据近六个月内多家机构对再生元制药公司的跟踪报道，正面观点占比较高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 再生元制药公司本季度营收预计增长20.91%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199198144","title":"异动解读｜再生元制药盘中上涨3.06%，Libtayo欧洲给药方案获积极监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1199198144","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199198144?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:45","pubTimestamp":1792503922,"startTime":"0","endTime":"0","summary":"10月20日，再生元制药盘中上涨3.06%，报806.0美元/股，成交额3739.78万美元。此次异动有明确消息面支撑。公司此前披露，欧洲药品管理局人用药品委员会建议批准Libtayo在欧盟所有已获批适应症中的更新给药方案，包括前12周每3周350毫克、此后每6周700毫克静脉输注，并建议在首次30分钟输注耐受良好后，将350毫克剂量输注时间缩短至15至30分钟。该进展意味着Libtayo用药便利性有望提升，最终决定仍待欧盟委员会未来数月作出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再生元制药上涨，Libtayo给药方案获欧洲积极进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111133633","title":"异动解读｜再生元制药公司盘中上涨3.58%，瑞银恢复覆盖并看好Dupixent潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1111133633","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111133633?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:51","pubTimestamp":1792072261,"startTime":"0","endTime":"0","summary":"10月15日，再生元制药公司盘中上涨3.58%，报797.04美元，成交额7375.49万美元。当日股价异动的直接催化来自机构评级上调。瑞银恢复覆盖该股并给予买入评级，认为重磅药物Dupixent的潜力被市场低估，带动资金情绪回暖。此外，公司近期基本面消息亦提供支撑。Pasatru在OPTIMA三期试验84周扩展结果中继续显示持续疗效且安全性与56周结果一致；该药已于8月获FDA批准用于成人FOP，长期数据进一步强化其商业化前景。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元制药盘中上涨，瑞银看好Dupixent潜力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675305232","title":"瑞银：恢复覆盖再生元制药(REGN.US) 并予“买入”评级 重磅药物Dupixent潜力被低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2675305232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675305232?lang=zh_cn&edition=full","pubTime":"2026-10-15 14:31","pubTimestamp":1792045885,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","LU0823434583.USD","LU2324357040.USD","LU0289739699.SGD","LU2362540622.SGD","LU0058720904.USD","LU2468319806.SGD","BK4588","BBH","LU1917777945.USD","BK4585","LU0320765992.SGD","LU2362541273.HKD","LU0823434740.USD","IBBQ","LU2106854487.HKD","LU2023250504.SGD","LU0882574055.USD","LU0053666078.USD","REGN","LU1974910355.USD","TBXU","LU2089984988.USD","LU0109394709.USD","LU0823416689.USD","LU0889565916.HKD","BK4139","LU2237438978.USD","LU2362541513.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170029273","title":"异动解读｜再生元制药公司盘中上涨3.09%，Pasatru长期试验数据强化获批后商业前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1170029273","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170029273?lang=zh_cn&edition=full","pubTime":"2026-10-15 00:29","pubTimestamp":1791995352,"startTime":"0","endTime":"0","summary":"10月15日，再生元制药公司盘中上涨3.09%，报775.6888美元，成交额2.38亿美元。推动股价异动的消息面，是公司披露Pasatru在OPTIMA三期试验84周扩展结果中继续显示持续疗效，并在安全性上与56周结果一致，进一步强化这款罕见病新药的长期治疗价值。具体看，Pasatru已于8月获FDA批准用于成人FOP。此次84周数据显示，该药可持续抑制新发异位骨化并减少疾病发作；试验共入组63名成人患者，其中58人完成至少84周双盲扩展阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元制药异动拉升，罕见病新药长期数据强化前景","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673036880","title":"摩根大通：将再生元制药公司(REGN.US)目标价从900美元上调至950美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673036880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673036880?lang=zh_cn&edition=full","pubTime":"2026-10-06 12:22","pubTimestamp":1791260532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2106854487.HKD","BK4582","LU0823416689.USD","LU2023250504.SGD","IBBQ","LU0289739699.SGD","LU0053666078.USD","LU0823434740.USD","LU2324357040.USD","BK4588","LU2362541273.HKD","LU2362541513.USD","LU2089984988.USD","REGN","LU1974910355.USD","LU2237438978.USD","IBB","UDN","LU0320765992.SGD","BBH","LU0882574055.USD","UUP","BK4585","LU1917777945.USD","LU2362540622.SGD","LU2468319806.SGD","BK4139","TBXU","LU0058720904.USD","LU0114720955.EUR","LU0109394709.USD","PGF","LU0823434583.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105158017","title":"异动解读｜再生元制药公司盘中下跌3.08%，Eylea竞争压力与联盟扩展交织引发市场分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=1105158017","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105158017?lang=zh_cn&edition=full","pubTime":"2026-10-01 22:37","pubTimestamp":1790865462,"startTime":"0","endTime":"0","summary":"10月1日，再生元制药公司盘中下跌3.08%，报734.94美元/股，成交额1.33亿美元。消息面上，公司当日宣布与赛诺菲扩大全球免疫学联盟，新增四款下一代长效抗体项目，再生元将获10亿美元预付款及最高70亿美元里程碑付款，双方将平分成本与利润。同日Argus将公司评级从持有上调至买入，目标价850美元。此外，此前RBC指出再生元在与赛诺菲的合作重新谈判中仍需争取更优条款，投资者对协议经济条款的期望存在分歧，多空因素交织下股价承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再生元盘中下跌，Eylea竞争加剧引发担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153528610","title":"异动解读｜再生元制药公司盘中下跌3.52%，报763.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153528610","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153528610?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:46","pubTimestamp":1790603193,"startTime":"0","endTime":"0","summary":"9月28日，再生元制药公司盘中下跌3.52%，报763.31美元/股，成交额5641.1万美元。再生元制药公司所在的生物科技行业中，个股中，Kodiak Sciences Inc.涨138.01%，Moderna, Inc.跌3.46%，吉利德科学跌0.35%，Lakewood-Amedex Biotherapeutics涨2.69%，安进涨0.57%。再生元制药公司于1988年在纽约州注册成立，是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物，核心业务覆盖多个治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127394018","title":"异动解读｜再生元制药盘中上涨3.05%，RBC称公司正考虑扩大与赛诺菲合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1127394018","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127394018?lang=zh_cn&edition=full","pubTime":"2026-09-03 00:58","pubTimestamp":1788368326,"startTime":"0","endTime":"0","summary":"9月2日，再生元制药盘中上涨3.05%，报848.935美元/股，成交额2.19亿美元。消息面上，RBC Capital Markets发布报告称，再生元可能将与赛诺菲的长期药物合作伙伴关系扩展至多款新免疫学药物。RBC指出，再生元可能寻求在全球范围内更均衡的利润分成安排，改变当前由赛诺菲先行承担大部分开发费用、再生元后续偿还的模式，不过财务收益短期内或难以显现。RBC维持对再生元\"与大盘持平\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元股价上扬，赛诺菲合作或迎新突破","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0254},{"period":"1month","weight":0.2186},{"period":"3month","weight":0.153},{"period":"6month","weight":0.265},{"period":"1year","weight":0.398},{"period":"ytd","weight":0.1716}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.006953},{"month":7,"riseRate":0.666667,"avgChangeRate":0.057379},{"month":8,"riseRate":0.555556,"avgChangeRate":0.023569},{"month":9,"riseRate":0.444444,"avgChangeRate":0.021216},{"month":10,"riseRate":0.416667,"avgChangeRate":0.004843},{"month":11,"riseRate":0.527778,"avgChangeRate":0.044035},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}